To provide better guidance to policy makers in health, policing, and social care, the harms that drugs cause need to be properly assessed. This task is not easy because of the wide range of ways in which drugs can cause harm. This study undertook a review of drug harms with the multicriteria decision analysis (MCDA) approach. This technology has been used successfully to lend support to decision makers facing complex issues characterised by many, conflicting objectives.
Summary
Background
Proper assessment of the harms caused by the misuse of drugs can inform policy makers in health, policing, and social care. We aimed to apply multicriteria decision analysis (MCDA) modelling to a range of drug harms in the UK.
Methods
Members of the Independent Scientific Committee on Drugs, including two invited specialists, met in a 1-day interactive workshop to score 20 drugs on 16 criteria: nine related to the harms that a drug produces in the individual and seven to the harms to others. Drugs were scored out of 100 points, and the criteria were weighted to indicate their relative importance.
Findings
MCDA modelling showed that heroin, crack cocaine, and metamfetamine were the most harmful drugs to individuals (part scores 34, 37, and 32, respectively), whereas alcohol, heroin, and crack cocaine were the most harmful to others (46, 21, and 17, respectively). Overall, alcohol was the most harmful drug (overall harm score 72), with heroin (55) and crack cocaine (54) in second and third places.
Interpretation
These findings lend support to previous work assessing drug harms, and show how the improved scoring and weighting approach of MCDA increases the differentiation between the most and least harmful drugs. However, the findings correlate poorly with present UK drug classification, which is not based simply on considerations of harm.
See also: The concept of 'drug harms', by Peter Cohen, Drugs and Alcohol Today, December 2010
November 1, 2010
The Lancet
Si deseas apoyar nuestro trabajo, considera realizar una donación. Nos comprometemos a que nuestra valiosa investigación esté accesible sin costo, pero para eso necesitamos de tu ayuda. Si todas las personas que leen nuestro contenido realizan una donación de tan solo €12 podremos apoyar nuestro trabajo durante tres años.
